Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1951 1
1952 1
1960 1
1963 1
1964 1
1970 1
1972 1
1973 3
1974 5
1975 39
1976 52
1977 50
1978 39
1979 34
1980 92
1981 153
1982 190
1983 170
1984 167
1985 191
1986 180
1987 217
1988 220
1989 277
1990 256
1991 302
1992 287
1993 336
1994 339
1995 347
1996 323
1997 377
1998 383
1999 421
2000 408
2001 415
2002 431
2003 498
2004 596
2005 594
2006 578
2007 647
2008 715
2009 780
2010 893
2011 988
2012 1029
2013 1111
2014 1149
2015 1267
2016 896
2017 786
2018 1072
2019 1023
2020 1119
2021 1149
2022 1036
2023 908
2024 369

Text availability

Article attribute

Article type

Publication date

Search Results

23,455 results

Results by year

Filters applied: . Clear all
Page 1
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.
Brudno JN, Lam N, Vanasse D, Shen YW, Rose JJ, Rossi J, Xue A, Bot A, Scholler N, Mikkilineni L, Roschewski M, Dean R, Cachau R, Youkharibache P, Patel R, Hansen B, Stroncek DF, Rosenberg SA, Gress RE, Kochenderfer JN. Brudno JN, et al. Among authors: hansen b. Nat Med. 2020 Feb;26(2):270-280. doi: 10.1038/s41591-019-0737-3. Epub 2020 Jan 20. Nat Med. 2020. PMID: 31959992 Free PMC article. Clinical Trial.
Fifty-five percent of patients who received Hu19-CD828Z T cells obtained complete remission. Hu19-CD828Z T cells had clinical anti-lymphoma activity similar to that of T cells expressing FMC63-28Z, an anti-CD19 CAR tested previously by our group, which contai …
Fifty-five percent of patients who received Hu19-CD828Z T cells obtained complete remission. Hu19-CD828Z T cells had clinical …
Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers.
Zheng C, Fass JN, Shih YP, Gunderson AJ, Sanjuan Silva N, Huang H, Bernard BM, Rajamanickam V, Slagel J, Bifulco CB, Piening B, Newell PHA, Hansen PD, Tran E. Zheng C, et al. Among authors: hansen pd. Cancer Cell. 2022 Apr 11;40(4):410-423.e7. doi: 10.1016/j.ccell.2022.03.005. Cancer Cell. 2022. PMID: 35413272 Free article.
Tumor-infiltrating neoantigen-reactive T cells can mediate regression of metastatic gastrointestinal cancers yet remain poorly characterized. ...Most neoantigen-reactive CD4(+) T cells from a patient with bile duct cancer also exhibited an exhausted phenotype but wi …
Tumor-infiltrating neoantigen-reactive T cells can mediate regression of metastatic gastrointestinal cancers yet remain poorly charac …
PD-L1-specific T cells.
Ahmad SM, Borch TH, Hansen M, Andersen MH. Ahmad SM, et al. Among authors: hansen m. Cancer Immunol Immunother. 2016 Jul;65(7):797-804. doi: 10.1007/s00262-015-1783-4. Epub 2016 Jan 2. Cancer Immunol Immunother. 2016. PMID: 26724936 Free PMC article. Review.
We have described naturally occurring PD-L1-specific T cells that recognize both PD-L1-expressing immune cells and malignant cells. Thus, PD-L1-specific T cells have the ability to modulate adaptive immune reactions by reacting to regulatory cells. ...This review su …
We have described naturally occurring PD-L1-specific T cells that recognize both PD-L1-expressing immune cells and malignant cells. T …
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, Hansen MJ, Jin F, Ayasoufi K, Hefazi M, Schick KJ, Walters DK, Ahmed O, Chappell D, Sahmoud T, Durrant C, Nevala WK, Patnaik MM, Pease LR, Hedin KE, Kay NE, Johnson AJ, Kenderian SS. Sterner RM, et al. Among authors: hansen mj. Blood. 2019 Feb 14;133(7):697-709. doi: 10.1182/blood-2018-10-881722. Epub 2018 Nov 21. Blood. 2019. PMID: 30463995 Free PMC article.
Chimeric antigen receptor T (CAR-T) cell therapy is a new pillar in cancer therapeutics; however, its application is limited by the associated toxicities. ...Finally, we generated GM-CSF-deficient CART19 cells through CRISPR/Cas9 disruption of GM-CSF during CAR-T …
Chimeric antigen receptor T (CAR-T) cell therapy is a new pillar in cancer therapeutics; however, its application is limited b …
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, Stetler-Stevenson M, Salem D, Yuan C, Pavletic S, Kanakry JA, Ali SA, Mikkilineni L, Feldman SA, Stroncek DF, Hansen BG, Lawrence J, Patel R, Hakim F, Gress RE, Kochenderfer JN. Brudno JN, et al. Among authors: hansen bg. J Clin Oncol. 2018 Aug 1;36(22):2267-2280. doi: 10.1200/JCO.2018.77.8084. Epub 2018 May 29. J Clin Oncol. 2018. PMID: 29812997 Free PMC article.
Purpose Therapies with novel mechanisms of action are needed for multiple myeloma (MM). T cells can be genetically modified to express chimeric antigen receptors (CARs), which are artificial proteins that target T cells to antigens. ...Cytokine-release syndrome toxi …
Purpose Therapies with novel mechanisms of action are needed for multiple myeloma (MM). T cells can be genetically modified to expres …
CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy.
Ledergor G, Fan Z, Wu K, McCarthy E, Hyrenius-Wittsten A, Starzinski A, Chang H, Bridge M, Kwek S, Cheung A, Bylsma S, Hansen E, Wolf J, Wong S, Shah N, Roybal KT, Martin T, Ye CJ, Fong L. Ledergor G, et al. Among authors: hansen e. Blood Adv. 2024 Jul 9;8(13):3562-3575. doi: 10.1182/bloodadvances.2023012416. Blood Adv. 2024. PMID: 38574299 Free PMC article.
They also possessed a significantly higher proportion of CD8+ T-effector memory cells. In contrast, patients with short-lived responses to treatment have increased frequencies of cytotoxic CD4+ CAR T cells. ...These findings shed new light on the role of cytotoxic C …
They also possessed a significantly higher proportion of CD8+ T-effector memory cells. In contrast, patients with short-lived respons …
Toxicities associated with adoptive cellular therapies.
Hansen DK, Dam M, Faramand RG. Hansen DK, et al. Best Pract Res Clin Haematol. 2021 Sep;34(3):101287. doi: 10.1016/j.beha.2021.101287. Epub 2021 Jul 24. Best Pract Res Clin Haematol. 2021. PMID: 34625233 Review.
Chimeric antigen receptor (CAR) T cell therapy is an effective strategy for the treatment of relapsed/refractory hematologic malignancies leading to the Food and Drug Administration (FDA) approval of five CAR T cell products. ...In this review, we will describe the …
Chimeric antigen receptor (CAR) T cell therapy is an effective strategy for the treatment of relapsed/refractory hematologic malignan …
T-cell derived extracellular vesicles prime macrophages for improved STING based cancer immunotherapy.
Hansen AS, Jensen LS, Gammelgaard KR, Ryttersgaard KG, Krapp C, Just J, Jønsson KL, Jensen PB, Boesen T, Johansen M, Etzerodt A, Deleuran BW, Jakobsen MR. Hansen AS, et al. J Extracell Vesicles. 2023 Aug;12(8):e12350. doi: 10.1002/jev2.12350. J Extracell Vesicles. 2023. PMID: 37525396 Free PMC article.
Here, we demonstrate that extracellular vesicles (EVs), derived from activated CD4(+) T cells (T-EVs), sensitizes macrophages to elevate STING activation, mediated by IFNgamma carried on the T-EVs. Our work support that T-EVs can disrupt the immune sup …
Here, we demonstrate that extracellular vesicles (EVs), derived from activated CD4(+) T cells (T-EVs), sensitizes macrophages …
Toxicity of CAR T-Cell Therapy for Multiple Myeloma.
Afrough A, Abraham PR, Turer L, Kaur G, Sannareddy A, Hansen DK, Anderson LD Jr. Afrough A, et al. Among authors: hansen dk. Acta Haematol. 2024 May 8:1-15. doi: 10.1159/000539134. Online ahead of print. Acta Haematol. 2024. PMID: 38718775 Review.
BACKGROUND: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are novel chimeric antigen receptor (CAR)-T cell therapies targeting B-cell maturation antigen (BCMA), and both have recently gained approval by the US Food Drug Administration (FDA) for …
BACKGROUND: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are novel chimeric antigen receptor (CAR)-T ce …
TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy.
Tvingsholm SA, Frej MS, Rafa VM, Hansen UK, Ormhøj M, Tyron A, Jensen AWP, Kadivar M, Bentzen AK, Munk KK, Aasbjerg GN, Ternander JSH, Heeke C, Tamhane T, Schmess C, Funt SA, Kjeldsen JW, Kverneland AH, Met Ö, Draghi A, Jakobsen SN, Donia M, Marie Svane I, Hadrup SR. Tvingsholm SA, et al. Among authors: hansen uk. J Immunother Cancer. 2023 Aug;11(8):e006847. doi: 10.1136/jitc-2023-006847. J Immunother Cancer. 2023. PMID: 37586765 Free PMC article.
The resulting T-cell products were assessed for phenotypic and functional characteristics. RESULTS: We identified an optimal Ag-scaffold for expansion of T-cells for ACT, carrying pMHC and interleukin-2 (IL-2) and IL-21, with which we efficiently expanded both virus …
The resulting T-cell products were assessed for phenotypic and functional characteristics. RESULTS: We identified an optimal Ag-scaff …
23,455 results
You have reached the last available page of results. Please see the User Guide for more information.